$CMPX Cashflow Statement | Understand Stock

$CMPX

$0.77 +$0.02 (2.54%) Live

$CMPX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Gain on disposal of equipment
Noncash interest expense
Share-based compensation
Change in fair value of derivative liability
Amortization of premium and discount on marketable securities
Write-off of in-process R&D
ROU asset amortization

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other long-term assets
Accounts payable
Accrued expenses
Operating lease liability
Settlement of derivative liability
Net cash used in operating activities

Cash flows from investing activities:
Purchases of marketable securities
Proceeds from sale or maturities of marketable securities
Purchase of property and equipment
Asset acquistion costs
Asset acquisition costs
Proceeds from sale of equipment
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Proceeds from issuance of common stock and warrants
Issuance costs from issuance of common stock
Proceeds from exercise of stock options
Repayment of borrowings under loan
Taxes paid related to net shares settlement of RSUs
Net cash provided by financing activities
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of period

Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents and restricted cash
Supplemental disclosure of cash flow information
Cash paid for interest
Conversion of preferred units
ROU asset acquired through operating leases
Issuance of common stock for acquisition of Trigr Therapeutics, Inc.
Fixed asset costs included in accrued expenses
ROU asset acquired through operating leases
Issuance of common stock for acquisition of Trigr Therapeutics, Inc.
Fixed asset costs included in accrued expenses
Unrealized gain (loss) on marketable securities

Comments